Aurobindo Pharma Limited — Updates, 13-12-2024: Press Release

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) for its biosimilar Zefylti (BP13), which is aimed at treating neutropenia. Zefylti will be available in two dosages: 30 MU/0.5 mL and 48 MU/0.5 mL. This marks a significant milestone as it is the first biosimilar from CuraTeQ to receive such endorsement following their recent GMP compliance certification from the EMA. Additionally, two other biosimilars are currently under review, with plans to bring these products to market next year. This development not only demonstrates CuraTeQ's growing capabilities in the biosimilars space but also opens avenues for increased revenue streams and market presence, particularly in oncology and immunology.